Progressive Familial Intrahepatic Cholestasis (PFIC) Cell Models for Research

Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare autosomal recessive disorder with an estimated incidence of 1 in 50,000 to 1 in 100,000 live births (WHO, 2023). PFIC accounts for 10-15% of pediatric liver transplantations in Europe and North America (NCI, 2023). Without treatment, PFIC progresses to end-stage liver disease within the first two decades of life. The 5-year survival for PFIC patients with native liver is approximately 50-70%, but post-transplant survival exceeds 90% (NCI, 2023). Key risk factors include consanguinity and family history. PFIC is a valuable research model because it represents a monogenic disease with clear genotype-phenotype correlations, enabling mechanistic studies of bile acid transport and hepatocyte function. Public datasets include the PFIC registry and ClinVar entries for ATP8B1, ABCB11, and ABCB4.

PFIC is ideal for studying cholestasis, bile acid toxicity, and liver fibrosis. The disease is caused by mutations in genes encoding canalicular transport proteins, providing a direct link between molecular defects and clinical phenotypes. PFIC subtypes (PFIC1, PFIC2, PFIC3) exhibit distinct genetic etiologies, allowing comparative studies. Open questions include the molecular mechanisms of disease progression, the role of bile acid signaling in hepatocyte injury, and the development of targeted therapies. Gene-edited cell models of PFIC are essential for functional validation of variants, drug screening, and understanding genotype-phenotype correlations.

PFIC is not a cancer, but chronic cholestasis can lead to hepatocellular carcinoma (HCC) in some patients. The major pathways involved include:

1. Bile acid-induced oxidative stress: Accumulation of toxic bile acids in hepatocytes leads to reactive oxygen species (ROS) production, mitochondrial dysfunction, and DNA damage.

2. Inflammatory signaling: Chronic inflammation activates NF-κB and STAT3 pathways, promoting cell proliferation and survival.

3. Fibrotic remodeling: Activation of hepatic stellate cells via TGF-β and PDGF pathways leads to liver fibrosis and cirrhosis.

4. Oncogenic transformation: In PFIC2, mutations in ABCB11 (BSEP) are associated with increased risk of HCC, possibly due to impaired bile acid export and accumulation of carcinogenic metabolites.

The following table summarizes the most frequently mutated genes in PFIC, based on ClinVar and COSMIC data (accessed 2023):

Data from ClinVar (NCBI, 2023) and COSMIC (Sanger Institute, 2023).

PFIC mutations disrupt multiple signaling networks:

• • Bile acid signaling: FXR (NR1H4) and SHP (NR0B2) regulate bile acid synthesis and transport. Loss of FXR leads to upregulation of CYP7A1 and increased bile acid synthesis.
• • Inflammatory pathways: NF-κB and JAK/STAT are activated in response to bile acid-induced injury.
• • Fibrotic pathways: TGF-β and PDGF signaling promote stellate cell activation.
• • Proliferative pathways: MAPK/ERK and PI3K/AKT are upregulated in hepatocytes, potentially leading to HCC.
• • Oxidative stress response: Nrf2/ARE pathway is induced, but chronic activation may contribute to carcinogenesis.

Common cell lines used for PFIC research include:

Organoids derived from patient iPSCs or liver biopsies retain PFIC mutations and recapitulate bile acid transport defects. They are useful for drug testing and disease modeling.

Animal models for PFIC include:

• • Genetically engineered mouse models (GEMMs): Atp8b1-deficient mice, Abcb11 knockout mice, Abcb4 knockout mice. These models exhibit cholestasis, fibrosis, and HCC.
• • Induced models: Bile duct ligation (BDL) in rodents induces cholestasis and fibrosis.
• • Patient-derived xenografts (PDX): Not commonly used for PFIC due to the non-cancerous nature, but PDX from PFIC-associated HCC can be used.
• • Zebrafish models: Knockdown of atp8b1 or abcb11 recapitulates liver phenotypes.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific PFIC mutations. For example, ATP8B1 knockout in HepG2 cells abolishes FIC1 function, while ABCB11 knockout models BSEP deficiency. Knock-in models can introduce point mutations (e.g., p.D482G in ABCB11) to study variant-specific effects. These gene-edited cell models are commercially available from sources such as cell line repositories and custom service providers. They are sequence-verified and validated for functional assays, accelerating research without the need for primary patient samples. Isogenic pairs (wild-type vs. mutant) allow direct comparison of phenotypic effects, reducing experimental variability.

Gene-edited cells are used to validate the functional impact of PFIC variants. For example, ATP8B1 knockout in HepG2 cells leads to reduced aminophospholipid flippase activity, as measured by phosphatidylserine externalization. ABCB11 knockout cells show impaired bile acid export, which can be rescued by wild-type ABCB11 expression. These models enable high-throughput screening to identify genetic modifiers or therapeutic targets.

Isogenic PFIC cell lines are used in drug screening to identify compounds that restore bile acid transport or reduce cholestatic injury. For example, FXR agonists like obeticholic acid can be tested in ABCB11 knockout cells to assess their ability to upregulate alternative transporters. Resistance studies involve exposing cells to increasing concentrations of bile acids to select for adaptive mutations, which can be identified by whole-genome sequencing.

CRISPR-based synthetic lethality screens in PFIC cell models can identify genes that, when silenced, selectively kill mutant cells. This approach can reveal novel therapeutic targets and biomarkers. For example, a screen in ABCB11 knockout cells might identify genes involved in bile acid detoxification that are essential for survival. Such biomarkers could be used for patient stratification or monitoring treatment response.